November 27, 2001

Dear Investigator:

This is to inform you that, effective November 17, 2001, ACAM IRB has suspended all operations.

After careful evaluation, the IRB has concluded that ACAM lacks the financial, administrative and professional resources to comply with the current FDA requirements and regulations for IRB oversight of human subject research.

ACAM will continue to seek affiliations, partnerships, or independent commercial organizations that can function as an effective IRB to facilitate clinical research by ACAM members.

We will notify you if and when such opportunities develop.

Sincerely,

Ralph A. Miranda, MD, FACAM
Chairman, IRB

RAM: Ia